DermTech Inc Equity-NMS: DMTK

DermTech, Inc. is a molecular diagnostics company. The Company is focused on developing and marketing non-invasive genomics tests to aid in the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. Its technology enhances early melanoma detection by non-invasively detecting genomic markers associated with melanoma to identify higher risk lesions at their earliest stages to rule out melanoma. It provides genomic analysis of skin samples collected non-invasively using its Smart Stickers. Its DermTech Melanoma Test (the DMT) facilitates the clinical assessment of pigmented skin lesions that raise the concern for melanoma. Its commercial test addresses unmet needs in the diagnostic pathway of pigmented skin lesions, dark-colored patches of skin often referred to as moles. It markets the DMT under the name Pigmented Lesion Assay (PLA). It is also focuses on products to assess precancerous genomic changes associated with UV sun exposure.